Matthew Fox, DSc

Associate Professor, Epidemiology
Matthew Fox
Crosstown Center – CT372
View full profile at BUMC


Matthew Fox, DSc, MPH, is Associate Professor in the Center for Global Health & Development and in the Department of Epidemiology at Boston University. Dr. Fox joined the Center in 2001. Before joining Boston University, he was a Peace Corps volunteer in the former Soviet Republic of Turkmenistan. His research interests include treatment outcomes in HIV-treatment programs, infectious disease epidemiology (with specific interests in HIV, pneumonia, and malaria), and epidemiologic methods. Dr. Fox is currently funded through a K award from the National Institutes of Allergy and Infectious Diseases, to work on ways to improve retention in HIV-care programs in South Africa from the time of testing HIV-positive through long-term treatment. As part of this work, he is involved in analyses of whether treating patients at higher CD4 counts leads to improved long-term retention and treatment outcomes. Dr. Fox also does research on quantitative sensitivity analysis and recently co-authored a book on these methods, Applying Quantitative Bias Analysis to Epidemiologic Data. He currently teaches a third-level epidemiologic methods class. Dr. Fox is a graduate of the Boston University School of Public Health with a master’s degree in epidemiology and biostatistics and a doctorate in epidemiology.


  • Bates College, BA
  • Boston University School of Public Health, MPH
  • Boston University School of Public Health, DSc

Classes Taught

  • SPHEP854
  • SPHEP860


  • Published on 3/25/2014

    Shearer K, Maskew M, Ajayi T, Berhanu R, Majuba P, Sanne I, Fox MP. Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.

    Read at: PubMed
  • Published on 3/3/2014

    Takuva S, Maskew M, Brennan AT, Long L, Sanne I, Fox MP. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17(1):18651.

    Read at: PubMed
  • Published on 3/3/2014

    Brennan AT, Shearer K, Maskew M, Long L, Sanne I, Fox MP. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.

    Read at: PubMed
  • Published on 1/1/2014

    Izadnegahdar R, Fox MP, Jeena P, Qazi SA, Thea DM. Revisiting Pneumonia and Exposure Status in Infants Born to HIV-infected Mothers. Pediatr Infect Dis J. 2014 Jan; 33(1):70-2.

    Read at: PubMed
  • Published on 12/3/2013

    Wandeler G, Gerber F, Rohr J, Chi BH, Orrell C, Chimbetete C, Prozesky H, Boulle A, Hoffmann CJ, Gsponer T, Fox MP, Zwahlen M, Egger M, Africa IS. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. Antivir Ther. 2013 Dec 3.

    Read at: PubMed
  • Published on 11/19/2013

    Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013; 16:18794.

    Read at: PubMed
  • Published on 8/27/2013

    Takuva S, Maskew M, Brennan AT, Sanne I, Macphail AP, Fox MP. Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART Regimen. J Trop Med. 2013; 2013:162950.

    Read at: PubMed
  • Published on 8/7/2013

    Shearer K, Fox MP, Maskew M, Berhanu R, Long L, Sanne I. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.

    Read at: PubMed
  • Published on 8/1/2013

    Maskew M, MacPhail AP, Whitby D, Egger M, Fox MP. Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults. J Acquir Immune Defic Syndr. 2013 Aug 1; 63(4):442-8.

    Read at: PubMed
  • Published on 7/30/2013

    Fox M, McCarthy O, Over M. A novel approach to accounting for loss to follow-up when estimating the relationship between CD4 Count at ART initiation and mortality. PLoS One. 2013; 8(7):e69300.

    Read at: PubMed

View 79 more publications:View full profile at BUMC